Albuvirtide LA is under clinical development by Frontier Biotechnologies and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Albuvirtide LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Albuvirtide LA overview
Albuvirtide (Aikening) is a 3-maleimimidopropionic acid (MPA)-modified peptide, acts as an anti-HIV agent. It is formulated as long-acting release injectable powder for solution for intravenous route of administration. Aikening is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with lopinavir or ritonavir (LPV/r) suppressed HIV replication in adults who failed the standard first-line antiretroviral drug.
FB-006M (albuvirtide) is under development for the treatment of human immunodeficiency virus (HIV) infection in combination with 3BNC-117 in the U.S.
Frontier Biotechnologies overview
Frontier Biotechnologies (Frontier) is a clinical-stage pharmaceutical company that offers drug discovery and development business models and clinical research services. The company’s pipeline products comprise FB1002, novel broad-spectrum HIV neutralizing antibody; FB3001, new transdermal patch for the treatment of musculoskeletal pain and FB2001, a novel coronavirus (SARS-CoV-2) protease inhibitor. It also offers Aikening, a HIV fusion inhibitor to treat human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). Frontier also carries out research and development activities in the field of HIV long-acting treatment and immunotherapy in China and the US. The company collaborates with manufacturers and commercial distributors to bring innovative drugs for unmet clinical needs. Frontier is headquartered in Nanjing, Jiangsu, China.
For a complete picture of Albuvirtide LA’s drug-specific PTSR and LoA scores, buy the report here.